公开(公告)号：WO2005098444A2

公开(公告)日：2005-10-20

申请号：PCT/US2004/021629

申请日：2004-07-06

Applicant: XENOPORT, INC. ,  ZERANGUE, Noa ,  BHAT, Laxminarayan

Inventor： ZERANGUE, Noa ,  BHAT, Laxminarayan

IPC: G01N33/574

CPC classification number: C07K14/705 ,  A61K31/195 ,  G01N33/5005 ,  G01N33/5011 ,  G01N33/6872 ,  G01N33/84 ,  G01N2500/00

Abstract: MCT1 and MCT4 are expressed at higher levels in many cancer cells than comparable normal cells of the same tissue. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the MCT1 and/or MCT4, as well as inhibitors and substrates of MCT1 and/or MCT4, methods of isolating the same, and methods of using the same for treatment or diagnosis of cancer.

Abstract translation: MCT1和MCT4在许多癌细胞中以比相同组织的相似正常细胞更高的水平表达。 本文公开了用于确定测试材料/分子是MCT1和/或MCT4以及MCT1和/或MCT4的抑制剂和底物的底物和/或由MCT1和/或MCT4主动转运的测定法，其分离方法 以及将其用于治疗或诊断癌症的方法。

公开(公告)号：WO2004052841A1

公开(公告)日：2004-06-24

申请号：PCT/US2003/038742

申请日：2003-12-08

Applicant: XENOPORT, INC. ,  XIANG, Jia-Ning ,  GALLOP, Mark, A. ,  CUNDY, Kenneth, C. ,  LI, Jianhua ,  XU, Feng ,  ZHOU, Cindy, X. ,  BHAT, Laxminarayan

Inventor： XIANG, Jia-Ning ,  GALLOP, Mark, A. ,  CUNDY, Kenneth, C. ,  LI, Jianhua ,  XU, Feng ,  ZHOU, Cindy, X. ,  BHAT, Laxminarayan

IPC: C07C243/18

CPC classification number: C07D213/30 ,  C07C243/18 ,  C07C281/02 ,  C07D295/088 ,  C07D307/89

Abstract: Prodrugs of carbidopa, derivatives of carbidopa prodrugs, methods of making prodrugs of carbidopa and derivatives thereof, methods of using prodrugs of carbidopa and derivatives thereof, and compositions of prodrugs of carbidopa and derivatives thereof are disclosed.

Abstract translation: 卡比多巴的前药，卡比多前药的衍生物，卡比多巴的前药及其衍生物的制备方法，使用卡比多巴的前药及其衍生物的方法，以及卡比多巴及其衍生物的前药组合物。

公开(公告)号：WO2010099502A1

公开(公告)日：2010-09-02

申请号：PCT/US2010/025687

申请日：2010-02-26

Applicant: REVIVA PHARMACEUTICALS, INC. ,  BHAT, Laxminarayan ,  MOHAPATRA, Prabhu, Prasad ,  ADIEY, Kouacou

Inventor： BHAT, Laxminarayan ,  MOHAPATRA, Prabhu, Prasad ,  ADIEY, Kouacou

IPC: A61K31/497

CPC classification number: C07D265/36 ,  A61K31/538 ,  C07D413/12

Abstract: The present invention provides arylpiperazine derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder and depression.

Abstract translation: 本发明提供了可有利地用于治疗精神分裂症和相关精神病例如急性躁狂症，双相情感障碍，自闭症和抑郁症的芳基哌嗪衍生物。

公开(公告)号：WO2005098444A3

公开(公告)日：2006-03-09

申请号：PCT/US2004021629

申请日：2004-07-06

Applicant: XENOPORT INC ,  ZERANGUE NOA ,  BHAT LAXMINARAYAN

Inventor： ZERANGUE NOA ,  BHAT LAXMINARAYAN

IPC: A61K31/195 ,  C07K14/705 ,  G01N33/50 ,  G01N33/574 ,  G01N33/68 ,  G01N33/84 ,  C12Q1/00

CPC classification number: C07K14/705 ,  A61K31/195 ,  G01N33/5005 ,  G01N33/5011 ,  G01N33/6872 ,  G01N33/84 ,  G01N2500/00

Abstract: MCT1 and MCT4 are expressed at higher levels in many cancer cells than comparable normal cells of the same tissue. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the MCT1 and/or MCT4, as well as inhibitors and substrates of MCT1 and/or MCT4, methods of isolating the same, and methods of using the same for treatment or diagnosis of cancer.

Abstract translation: MCT1和MCT4在许多癌细胞中以比相同组织的相似正常细胞更高的水平表达。 本文公开了用于确定测试材料/分子是MCT1和/或MCT4以及MCT1和/或MCT4的抑制剂和底物的底物和/或由MCT1和/或MCT4主动转运的测定法，其分离方法 以及将其用于治疗或诊断癌症的方法。

公开(公告)号：WO2003080588A1

公开(公告)日：2003-10-02

申请号：PCT/US2003/008736

申请日：2003-03-20

Applicant: XENOPORT ,  GALLOP, Mark, A. ,  XIANG, Jia-Ning ,  YAO, Fenmei ,  BHAT, Laxminarayan

Inventor： GALLOP, Mark, A. ,  XIANG, Jia-Ning ,  YAO, Fenmei ,  BHAT, Laxminarayan

IPC: C07D307/83

CPC classification number: C07D307/89 ,  C07D309/30 ,  C07D313/04

Abstract: The present invention provides cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, methods of making cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs. The present invention also provides methods of using cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs.

Abstract translation: 本发明提供GABA类似物的环状1-（酰氧基） - 烷基前体药物，制备GABA类似物的环状1-（酰氧基） - 烷基前体药物的方法和GABA类似物的环状1-（酰氧基）烷基前体药物的组合物。 本发明还提供了使用GABA类似物的环状1-（酰氧基） - 烷基前体药物和GABA类似物的环状1-（酰氧基） - 烷基前体药物组合物的方法。

公开(公告)号：WO2009154993A1

公开(公告)日：2009-12-23

申请号：PCT/US2009/045320

申请日：2009-05-27

Applicant: REVIVA PHARMACEUTICALS, INC. ,  MOHAPATRA, Prabhu, Prasad ,  BHAT, Laxminarayan ,  ADIEY, Kouacou

Inventor： MOHAPATRA, Prabhu, Prasad ,  BHAT, Laxminarayan ,  ADIEY, Kouacou

IPC: A01N43/00

CPC classification number: C07D265/36 ,  C07D239/96

Abstract: The present invention provides novel piperazine derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder and depression.

Abstract translation: 本发明提供了可有利地用于治疗精神分裂症和相关精神病如急性躁狂症，双相情感障碍，自闭症和抑郁症的新型哌嗪衍生物。

公开(公告)号：WO2008144764A1

公开(公告)日：2008-11-27

申请号：PCT/US2008/064433

申请日：2008-05-21

Applicant: REVIVA PHARMACEUTICALS, INC. ,  BHAT, Laxminarayan ,  MOHAPATRA, Prabhu, P. ,  BHAT, Seema, Rani

Inventor： BHAT, Laxminarayan ,  MOHAPATRA, Prabhu, P. ,  BHAT, Seema, Rani

IPC: A61K31/497

CPC classification number: C07D215/22 ,  C07D215/48

Abstract: The present invention provides novel quinolinone derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression.

Abstract translation: 本发明提供了可有利地用于治疗精神分裂症和相关精神病如急性躁狂症，双相情感障碍，自闭症和抑郁症的新型喹啉酮衍生物。

公开(公告)号：WO2003020214A3

公开(公告)日：2003-03-13

申请号：PCT/US2002/027458

申请日：2002-08-29

Applicant: XENOPORT, INC. ,  BHAT, Laxminarayan ,  GALLOP, Mark, A. ,  JANDELEIT, Bernd

Inventor： BHAT, Laxminarayan ,  GALLOP, Mark, A. ,  JANDELEIT, Bernd

IPC: C07J9/00

Abstract: Disclosed are compounds that exhibit high transport across the intestinal wall of an animal. The compounds may optionally be linked to drugs that are poorly absorbed or poorly transported across the intestinal wall after oral administration to provide for enhanced therapeutic, and optionally prolonged therapeutic, systemic blood concentrations of the drugs upon oral administration of the drug-compound conjugate. Also disclosed are pharmaceutical compositions containing and methods of using such compounds.

公开(公告)号：WO2012003501A3

公开(公告)日：2012-03-29

申请号：PCT/US2011042887

申请日：2011-07-01

Applicant: REVIVA PHARMACEUTICALS INC ,  BHAT LAXMINARAYAN ,  ADIEY KOUACOU

Inventor： BHAT LAXMINARAYAN ,  ADIEY KOUACOU

IPC: C12P7/64

CPC classification number: C07C69/34 ,  C07C69/96 ,  C07C209/48 ,  C07C209/88 ,  C07C211/26 ,  C07C213/06 ,  C07C213/10 ,  C07C217/74 ,  C07C219/06 ,  C07C229/34 ,  C07C231/02 ,  C07C237/06 ,  C07C237/22 ,  C07C271/20 ,  C07C2601/04

Abstract: The present invention provides novel cycloalkylmethylamme derivatives, and methods of preparing cycloalkylmethylamme derivatives. The present invention also provides methods of using cycloalkylmethylamme derivatives and compositions of cycloalkylmethylamme derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.

Abstract translation: 本发明提供新的环烷基甲基胺衍生物，以及环烷基甲基胺衍生物的制备方法。 本发明还提供了使用环烷基甲基胺衍生物和环烷基甲基胺衍生物的组合物的方法。 本发明化合物的药物组合物可以有利地用于治疗和/或预防肥胖和肥胖相关并发症适应症和抑郁症和抑郁症相关并发症的适应症。

公开(公告)号：WO2012003501A2

公开(公告)日：2012-01-05

申请号：PCT/US2011/042887

申请日：2011-07-01

Applicant: REVIVA PHARMACEUTICALS, INC. ,  BHAT, Laxminarayan ,  ADIEY, Kouacou

Inventor： BHAT, Laxminarayan ,  ADIEY, Kouacou

IPC: C12P7/64

CPC classification number: C07C69/34 ,  C07C69/96 ,  C07C209/48 ,  C07C209/88 ,  C07C211/26 ,  C07C213/06 ,  C07C213/10 ,  C07C217/74 ,  C07C219/06 ,  C07C229/34 ,  C07C231/02 ,  C07C237/06 ,  C07C237/22 ,  C07C271/20 ,  C07C2601/04

Abstract: The present invention provides novel cycloalkylmethylamme derivatives, and methods of preparing cycloalkylmethylamme derivatives. The present invention also provides methods of using cycloalkylmethylamme derivatives and compositions of cycloalkylmethylamme derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.

Abstract translation: 本发明提供了新的环烷基甲基胺衍生物，以及制备环烷基甲基胺衍生物的方法。 本发明还提供了使用环烷基甲基胺衍生物和环烷基甲基胺衍生物组合物的方法。 本发明化合物的药物组合物可以有利地用于治疗和/或预防肥胖症和肥胖症相关的共病迹象以及抑郁症和抑郁症相关的共病症状。